AnelleO is a medical device company that is developing a 3D printed intravaginal ring that can be used as a platform for treating a wide range of women's health conditions. Their first product, AnelleO PRO involves the only single administration of progesterone for infertility. Their technology enables controlled drug-release kinetics with up to 100% drug release, as well as rapid manufacturing and custom sizing. The manufacturing method allows for formulation of biologics and drug combinations not possible with traditional technologies. AnelleO was founded by Rahima Benhabbour, professor at the Eshelman School of Pharmacy/UNC_NCSU Joint Biomedical Engineering Department, and Post Doctoral Fellow Rima Janusziewicz.
Hemophilia is treated with gene therapy to replace clotting factors. In a large number of patients, the treatment induces inhibitory antibodies which counteract the therapeutic effect. This technology fulfills the need for a treatment for hemophilia and other blood disorders which does not trigger inhibitors. It works by delivering AAV to the liver and producing a therapeutic protein which increases clotting without inducing inhibitors.
SOVE is making a new approach for orthodontics. Traditional braces have never been comfortable or attractive, therefore there has been a large movement in the market towards invisible braces. However, many current 'invisible' alternatives suffer from a range of compromises that can make them under-perform. SOVE is developing the 2Insight, a two-stage orthodontic system that eliminate the problems associated with esthetic orthodontic appliances.